Veradermics, Inc 8-K

What Happened

• Veradermics, Inc. announced it closed an underwritten public offering on May 1, 2026 of 3,843,790 shares of common stock at $100.00 per share, generating gross proceeds of $384,379,000 (before underwriting discounts and commissions). The underwriters have a 30‑day option to buy up to an additional 576,568 shares at the public offering price.
• Concurrently, Veradermics closed a private placement under a Securities Purchase Agreement dated April 29, 2026, selling pre‑funded warrants to affiliated Suvretta Capital entities to purchase an aggregate of 300,000 shares of common stock at $99.99999 per pre‑funded warrant, producing gross proceeds of approximately $30.0 million (before placement agent fees and expenses).

Key Details

• Public offering: 3,843,790 shares at $100.00 each; gross proceeds $384,379,000; 30‑day option for 576,568 additional shares.
• Private placement: 300,000 pre‑funded warrants at $99.99999 each; gross proceeds ~ $30.0M; each warrant exercisable for one share at $0.00001 exercise price (cash or cashless).
• Pre‑funded warrants are unregistered and issued under Section 4(a)(2) exemption; exercise limited so holder’s post‑exercise beneficial ownership cannot exceed 9.99% (can be increased up to 19.99% with notice and delay).
• The Purchase Agreement includes customary representations, closing conditions, indemnities and a 90‑day restriction on issuing/selling shares or convertible securities (subject to exceptions).

Why It Matters

• These transactions raise substantial capital for Veradermics: approximately $384.4M from the public offering and $30.0M from the private placement before fees, with potential additional proceeds if the underwriter option is exercised. That increases cash resources and may affect share count and dilution depending on exercise of warrants and any option take‑up.
• Investors should note the pre‑funded warrants are unregistered, have transfer/exercise limits, and the company agreed to a temporary restriction on issuing additional securities, all of which can affect liquidity and near‑term dilution.